Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 20/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20239353 | 1.00 | RORC (0.59) | RORC | |
| SCHEMBL20239345 | 1.00 | RORC (0.59) | RORC | |
| SCHEMBL16799959 | 0.88 | RORC (0.76) | RORC | |
| SCHEMBL16799539 | 0.86 | RORC (0.63) | RORC | |
| SCHEMBL18151481 | 0.85 | RORC (0.59) | RORC | |
| SCHEMBL18151480 | 0.84 | RORC (0.58) | RORC | |
| SCHEMBL18151488 | 0.84 | RORC (0.64) | RORC | |
| SCHEMBL16799514 | 0.84 | RORC (0.57) | RORC | |
| SCHEMBL16799557 | 0.84 | RORC (0.58) | RORC | |
| SCHEMBL20931327 | 0.83 | RORC (0.47) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110352054-B | ROR gamma modulators | 领先制药控股公司 | 2022-11-01 | — | — | CN | claimed |
| US-11299456-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA HOLDING B.V. (NL) | 2022-04-12 | — | — | US | claimed |
| EP-3548016-B1 | ROR-GAMMA (RORY)-MODULATORS | LEAD PHARMA B V (NL) | 2020-09-02 | — | — | EP | claimed |
| US-20200190028-A1 | ROR GAMMA (RORy) MODULATORS | SANOFI (FR) | 2020-06-18 | — | — | US | claimed |
| EP-3548016-A1 | ROR GAMMA (RORy) MODULATORS | Lead Pharma Holding B.V. (NL) | 2019-10-09 | — | — | EP | claimed |
| US-20190119204-A1 | ROR GAMMA (RORy) MODULATORS | SANOFI (FR) | 2019-04-25 | — | — | US | claimed |
| US-10196350-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA HOLDING B.V. (NL) | 2019-02-05 | — | — | US | claimed |
| US-20180162808-A1 | ROR GAMMA (RORy) MODULATORS | SANOFI (FR) | 2018-06-14 | — | — | US | claimed |
| WO-2018104288-A1 | ROR gamma (RORy) modulators | LEAD PHARMA HOLDING B.V. (NL) | 2018-06-14 | — | — | WO | claimed |
| CN-110352054-B | ROR gamma modulators | 领先制药控股公司 | 2022-11-01 | — | — | CN | disclosed |
| US-11299456-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA HOLDING B.V. (NL) | 2022-04-12 | — | — | US | disclosed |
| EP-3548016-B1 | ROR-GAMMA (RORY)-MODULATORS | LEAD PHARMA B V (NL) | 2020-09-02 | — | — | EP | disclosed |
| EP-3548016-B1 | ROR-GAMMA (RORY)-MODULATORS | LEAD PHARMA B V (NL) | 2020-09-02 | — | — | EP | disclosed |
| US-20200190028-A1 | ROR GAMMA (RORy) MODULATORS | SANOFI (FR) | 2020-06-18 | — | — | US | disclosed |
| US-10196350-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA HOLDING B.V. (NL) | 2019-02-05 | — | — | US | disclosed |
| WO-2018104288-A1 | ROR gamma (RORy) modulators | LEAD PHARMA HOLDING B.V. (NL) | 2018-06-14 | — | — | WO | disclosed |
| US-20180162808-A1 | ROR GAMMA (RORy) MODULATORS | SANOFI (FR) | 2018-06-14 | — | — | US | disclosed |
| WO-2018104288-A1 | ROR gamma (RORy) modulators | LEAD PHARMA HOLDING B.V. (NL) | 2018-06-14 | — | — | WO | disclosed |
| US-20180162808-A1 | ROR GAMMA (RORy) MODULATORS | SANOFI (FR) | 2018-06-14 | — | — | US | disclosed |
| US-20180162808-A1 | ROR GAMMA (RORy) MODULATORS | SANOFI (FR) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190028-A1 | ROR GAMMA (RORy) MODULATORS | RORB, RORA, RORC | RORC 3/4885 |
| US-11299456-B2 | ROR gamma (RORγ) modulators | RORB, RORC, RORA | RORC 2/4885 |
| US-10196350-B2 | ROR gamma (RORγ) modulators | RORB, RORC, RORA | RORC 2/4885 |
| US-20190119204-A1 | ROR GAMMA (RORy) MODULATORS | RORB, RORA, RORC | RORC 3/4885 |
| US-20180162808-A1 | ROR GAMMA (RORy) MODULATORS | RORB, RORA, RORC | RORC 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.